[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349078-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349078-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-detection-of-urological-malignancies-in-lynch-syndrome-a-systematic-review","Early detection of urological malignancies in Lynch syndrome - a systematic review","","Lynch syndrome predisposes individuals to multiple cancers, including urological malignancies, yet evidence-based surveillance recommendations remain limited. This systematic review summarizes current evidence on surveillance strategies by performing a MEDLINE search for Lynch syndrome, urological malignancies, and surveillance methods, then calculating sensitivity and specificity when possible. Risk of bias was evaluated using the Newcastle–Ottawa Scale. Nine studies (2008–2025) met inclusion criteria. PSA surveillance identified 38 prostate cancers among 865 individuals, with 71% clinically significant; urothelial surveillance diagnosed 11 cancers in 1564 individuals and missed 15. Sensitivity and specificity varied across tests, while data suggest PSA promise for prostate surveillance and urine microsatellite instability promise for MSH2-associated urothelial cancer.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-detection-of-urological-malignancies-in-lynch-syndrome-a-systematic-review/349078/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-detection-of-urological-malignancies-in-lynch-syndrome-a-systematic-review/349078.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is a systematic review needed for urological malignancies in Lynch syndrome?","Question",{"text":63,"@type":64},"Lynch syndrome increases risk of urological cancers, but there are no evidence-based, consensus surveillance recommendations for these malignancies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What surveillance approach was evaluated for prostate cancer, and what were the results?",{"text":68,"@type":64},"Prostate-specific antigen (PSA) surveillance led to 38 prostate cancer diagnoses among 865 individuals with Lynch syndrome, and 71% were clinically significant.",{"name":70,"@type":61,"acceptedAnswer":71},"How did urothelial cancer surveillance performance vary across tests?",{"text":72,"@type":64},"Sensitivity differed by method: urinalysis 11%, urine cytology 30%, urine MSI 100%, and CT plus cystoscopy 100%. Specificity ranged from 90% to 100% depending on the test.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349078,1790176851,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":26,"preview_urls":147},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Familial Cancer (2026) 25:45  \n[https://doi.org/10.1007/s10689-026-00560-5](https://doi.org/10.1007/s10689-026-00560-5)  \nREVIEW  \nEarly detection of urological malignancies in Lynch syndrome: a systematic review  \nB. H. J. Doornweerd1 · M. W. Rasmussen2  \nReceived: 19 January 2026 / Accepted: 12 April 2026 © The Author(s) 2026  \nAbstract  \nLynch syndrome predisposes to multiple cancer types, including urological malignancies. However, no evidence-based recommendations for surveillance of urological malignancies currently exist. In this systematic review, we aim to describe the current evidence regarding surveillance for these cancers. A systematic literature search was conducted using MEDLINE, searching for urological malignancies, Lynch syndrome, and surveillance including the results of the surveillance methods. Sensitivity and specificity were calculated, when possible, preferably for pooled data from each surveillance method. The risk of bias was assessed using the Newcastle–Ottawa Scale. After full text-screening, nine studies published in 2008–2025 met the inclusion criteria, including two on prostate cancer and seven on urothelial cancer. Prostate cancerantigen (PSA) surveillance led to 38 prostate cancer diagnoses in 865 individuals with Lynch syndrome, with 71% being clinically significant prostate cancers. In 1564 individuals, 11 urothelial carcinomas were diagnosed by different surveillance methods and 15 diagnoses were missed. Sensitivity of urinalysis, urine cytology, urine MSI, and CT and cystoscopy was 11%, 30%, 100%, and 100% respectively. Specificity was 90%, 97%, 99%, and 100% respectively for these methods. Further data is needed but for prostate cancer surveillance PSA shows promise, while for MSH2 carriers at least, urine microsatellite instability analysis shows promise as a urothelial cancer surveillance test.  \nKeywords Lynch syndrome · Urothelial carcinoma · Hereditary cancer · Prostate cancer · Surveillance · Cancer prevention  \nIntroduction  \nLynch syndrome (LS) is a hereditary cancer predisposition syndrome caused by pathogenic variants in the mismatch repair (MMR) genes MLH1, MSH2 (including epigenetic silencing through EPCAM), MSH6, and PMS2 [1] . Individuals with LS are at increased risk of developing cancer at a younger age than those with sporadic cancer. In addition to the well-established elevated risks for colorectal and endometrial cancer, LS is also associated with an increased risk of urological malignancies, including cancer of the prostate,  \n􀀍 B. H. J. Doornweerd[b.h.j.doornweerd@umcg.nl](b.h.j.doornweerd@umcg.nl)  \n1 Department of Urology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands  \n2 The Danish HNPCC Register, Gastro Unit, Copenhagen University Hospital-Amager and Hvidovre, Copenhagen, Denmark  \nureter and kidney, and urinary bladder [2–5] . Little is known about the risk in LS for rare urological malignancies such as germ cell tumors of the testis or penile carcinoma. A small number of testicular cancers has been reported in a large LS database and an association of germ cell tumors with LS might exist, but testicular cancer is rarely the first cancer diagnosed in LS [6–8] . An increased incidence of renal cell carcinoma has been reported as well [9], but in general, renal cell carcinoma, germ cell tumors and penile cancer are not considered as being associated with LS.  \nCumulative incidence for prostate cancer (PC) at 75 years is approximately 24% for male MSH2 carriers [2] and clinically significant PC is more frequently observed in carriers of pathogenic MSH2 variants compared with non-carriers [10] . Urothelial carcinoma (UC) of the upper urinary tract and bladder are common malignancies in MSH2 carriers with a cumulative incidence at 75 years of approximately 18–19% and 8–13%, respectively [2] . While the most common malignant cause of death for LS individuals is  \n1 3  \ncolorectal carcinoma, both PC and UC are among common malig","cbCaibTOdWMIHcyJ","https://ap.wps.com/l/cbCaibTOdWMIHcyJ","pdf",1023027,11,"English","# Abstract\n# Introduction\n## Rationale for surveillance in Lynch syndrome\n## Prostate cancer surveillance approaches (PSA, MRI, biopsy)\n## Urothelial cancer surveillance approaches (urinalysis, cytology, MSI, CT, cystoscopy)\n# Methods\n## Review framework (PRISMA 2020)\n## Search, screening, extraction, and quality assessment","[{\"question\":\"Why is a systematic review needed for urological malignancies in Lynch syndrome?\",\"answer\":\"Lynch syndrome increases risk of urological cancers, but there are no evidence-based, consensus surveillance recommendations for these malignancies.\"},{\"question\":\"What surveillance approach was evaluated for prostate cancer, and what were the results?\",\"answer\":\"Prostate-specific antigen (PSA) surveillance led to 38 prostate cancer diagnoses among 865 individuals with Lynch syndrome, and 71% were clinically significant.\"},{\"question\":\"How did urothelial cancer surveillance performance vary across tests?\",\"answer\":\"Sensitivity differed by method: urinalysis 11%, urine cytology 30%, urine MSI 100%, and CT plus cystoscopy 100%. Specificity ranged from 90% to 100% depending on the test.\"}]","Early detection of urological malignancies in Lynch syndrome - a systematic review | PDF",1790081522,28,[148,152],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/7b69a382f7df5e8adaea2164233c747f.webp",983,1306,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/0068a58c748bc214064764b81d80d640.webp",982,1304]